Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

In recent years, the scientific community has made significant strides in the field of gene editing, particularly through the development of the CRISPR (Clustered Regularly Interspaced Short ...

CRISPR-Cas13, a powerful RNA-targeting technology is gaining increasing attention as a next-generation gene therapy platform due to its precision and reduced side effects. Utilizing this system, ...

Last year, a ten-month-old baby in the US was the first person in the world to have their rare genetic disease effectively ...

When a neuron in our body gets damaged, segments of RNA produce proteins that can help repair the injury. But in neurological disorders such as ALS and spinal muscular atrophy, or following spinal ...

How CRISPR and functional genomics are used to establish causality, understand disease mechanisms and guide early drug ...

AI‑driven protein design creates potent anti‑CRISPR inhibitors that block Cas13 activity, offering a new potential tool for safer, more controlled gene editing.

A landmark Huntington's trial slows disease progression by 75%, signalling how RNA- and CRISPR-based tools redefine treatment for rare genetic disorders. Significant advancements in gene silencing and ...

The era of genetic medicine has arrived. As scientists continue to unravel the mysteries of humanity’s genetic blueprint, their discoveries are driving the emergence of new types of therapies such as ...